May 2025 PBAC meeting to consider new MS treatment
25 February 2025
The Pharmaceutical Benefits Advisory Committee (PBAC) will consider ublituximab (Briumvi®) for treating relapsing remitting MS at their May 2025 meeting.
The Pharmaceutical Benefits Advisory Committee (PBAC) will consider ublituximab (Briumvi®) for treating relapsing remitting MS at their May 2025 meeting.
Bunbury local Lynda Whitton, a dedicated champion for people living with multiple sclerosis (MS), has been awarded MS Australia’s highest honour, the 2024 John Studdy Award.
Tamworth’s Marianne Gaul AM, an acclaimed nurse and dedicated volunteer, has been awarded the 2024 MS Advocate Award by MS Australia.
Newcastle’s Professor Jeannette Lechner-Scott, an internationally recognised neurologist and leader in multiple sclerosis (MS) research and clinical care, has been awarded the 2024 MS Research Award by MS Australia.
As we step into an uncertain 2025, CEO Rohan Greenland highlights seven key initiatives set to bring optimism to the MS Community.
As co-authors of a new scientific paper, people with MS spoke about their experiences of direct involvement in medical research.
Researchers and people living with MS have shortlisted antiviral medications targeting EBV for clinical trials in MS.
Researchers have found that higher levels of omega-6 polyunsaturated fatty acids in the blood are linked to a lower risk of developing MS.
In 2015, 21-year-old Cass David was working in a Melbourne dental clinic and considering a career in nursing. But then, she began to feel unwell. Â “The maxillofacial surgeon I worked with at the clinic told me to get an MRI. I did, and soon found out I had MS.”